What are the disadvantages of fine needle aspiration cytology (FNAC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Disadvantages of Fine Needle Aspiration Cytology (FNAC)

FNAC has several important limitations including dependence on operator expertise and cytopathologist availability, inability to assess tissue architecture, risk of sampling error, and diagnostic challenges in specific lesion types.

Technical and Procedural Limitations

Location-Dependent Technical Difficulty

The degree of technical difficulty varies significantly based on lesion location 1. Transduodenal FNAs (such as pancreatic uncinate or bile duct masses) are particularly challenging because the acutely angulated echoendoscope tip creates two problems: the needle assembly cannot be secured freely to the biopsy channel, and the FNA needle cannot be advanced freely into the target lesion 1. The echoendoscope becomes relatively unstable in the short scope position and tends to recoil into the stomach during the FNA motion 1.

Sampling Errors and Inadequate Specimens

Sampling error is a major disadvantage, particularly when targeting the necrotic center of masses rather than the periphery 1. Studies show that 3.5% of samples are inadequate, with 33.3% of these later diagnosed as metastatic carcinoma on histological examination 2. Additionally, 4.5% of samples initially diagnosed as benign were actually metastatic carcinoma, suggesting sampling errors 2.

Diagnostic Limitations

Inability to Assess Tissue Architecture

FNAC cannot provide histologic architecture, which is essential for diagnosing certain neoplasms including stromal cell tumors, lymphomas, and some benign diseases 1. This represents a fundamental limitation compared to core needle biopsy. The technique yields cytologic samples rather than preserved tissue architecture needed for definitive pathologic assessment 1.

False-Negative Diagnoses

Several scenarios lead to false-negative results 3, 4:

  • Pauci-cellular lesions (such as lobular carcinomas) often yield insufficient diagnostic material 3
  • Low-grade lymphomas that mimic reactive lymphoid populations 4
  • Aspirates with paucity of lesional cells due to sampling error or the intrinsic nature of certain entities like nodular lymphocyte predominant Hodgkin lymphoma 4
  • Ductal carcinoma in situ can lead to both false-negative and false-positive diagnoses 3

False-Positive Diagnoses

Certain benign conditions can mimic malignancy 3, 4:

  • Complex sclerosing lesions, fibroadenomas, and papillary lesions may show concerning features 3
  • Viral-associated lymphadenopathy and Kikuchi-Fujimoto lymphadenitis can mimic malignancy 4
  • Inflammatory pathologies such as steatonecrosis 3
  • Benign adnexal lesions mimicking metastatic malignancy 4

Dependence on Cytopathology Support

Critical Role of Onsite Cytopathologist

The absence of an onsite cytopathologist significantly reduces diagnostic yield 1. Studies demonstrate:

  • Diagnostic yield drops from 78-97% with onsite pathology to 32-86% without 1
  • Indeterminate samples increase from 2.1-10% to 10.3-47% without onsite support 1
  • Unsatisfactory samples increase from 0-1% to 13-20% without onsite pathology 1

This is particularly problematic as more than 50 advanced endoscopy fellows graduate annually in the US and relocate to smaller cities where access to onsite cytopathology is limited 1.

Need for Multiple Passes

Without onsite cytopathology, at least 3 passes must be performed on lymph nodes and 6-7 passes on pancreatic masses to maximize diagnostic yield 1. This increases procedure time and patient discomfort.

Specific Diagnostic Challenges

Indeterminate Results

FNAC can be indeterminate even with expert technique, particularly when 1:

  • Evaluating pancreatic masses in the background of chronic pancreatitis
  • Sampling uncinate process lesions that are difficult to visualize
  • Cytology interpretation is inherently difficult

The diagnostic yield plateaus after 7-8 passes, and persisting beyond this yields mostly bloody, nondiagnostic specimens 1. Repeat EUS-guided FNA yields correct diagnosis in only 61-84% of patients 1.

Tumor Classification Errors

FNAC has limitations in distinguishing between certain tumor types 4:

  • Metastatic carcinoma, sarcoma, melanoma, and lymphoma can mimic each other
  • Hodgkin lymphoma and its mimics are difficult to differentiate
  • High-grade lesions are impossible to distinguish from invasive carcinomas 3

Limited Expertise and Standardization

Expertise in FNAC is low in the developed world due to preference for core needle biopsies 3. The lack of standardized and uniform reporting systems for soft tissue FNAC represents a significant disadvantage 5. While the International Academy of Cytology established the Yokohama system to enhance diagnostic precision, variations in technique and subjective interpretation continue to present diagnostic challenges 3.

Common Pitfalls

Diagnostic difficulties relate to 6:

  • Deviations from common cytological criteria in some lesions
  • Effects of the sampling procedure itself
  • Effects of sample preparation methods
  • Loss of background mucin in liquid prep specimens, which is problematic for diagnosing mucin-producing pancreatic tumors 1

References

Guideline

best practices in endoscopic ultrasound-guided fine-needle aspiration.

Clinical Gastroenterology and Hepatology, 2012

Research

Role of fine needle aspiration cytology in the diagnosis of soft tissue tumours.

Cytopathology : official journal of the British Society for Clinical Cytology, 2020

Research

Pitfalls in fine needle aspiration cytology.

Cytopathology : official journal of the British Society for Clinical Cytology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.